

# Yeow Tee Goh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5778857/publications.pdf>

Version: 2024-02-01

57  
papers

1,115  
citations

759233

12  
h-index

414414

32  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1873  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 966-974.   | 10.7 | 345       |
| 2  | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.   | 13.7 | 187       |
| 3  | Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. <i>Blood</i> , 2014, 123, 4136-4142.  | 1.4  | 125       |
| 4  | Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2015, 121, 2185-2192.   | 4.1  | 51        |
| 5  | Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. <i>Lancet Haematology</i> , the, 2015, 2, e326-e333.  | 4.6  | 50        |
| 6  | Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. <i>Leukemia</i> , 2020, 34, 3413-3419.   | 7.2  | 42        |
| 7  | Pharmacokinetics and safety of ixazomib plus lenalidomide+dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. <i>Journal of Hematology and Oncology</i> , 2015, 8, 103.  | 17.0 | 37        |
| 8  | Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. <i>Blood</i> , 2020, 136, 47-50. | 1.4  | 37        |
| 9  | Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2447-2457.               | 1.6  | 36        |
| 10 | High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 143.   | 6.2  | 17        |
| 11 | MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7002-7002.                         | 1.6  | 17        |
| 12 | Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035. <i>Blood</i> , 2008, 112, 3226-3226. | 1.4  | 13        |
| 13 | Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2015, 169, 754-756.                                      | 2.5  | 12        |
| 14 | The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2336-2341.  | 1.3  | 12        |
| 15 | International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. <i>Blood Advances</i> , 2022, 6, 5516-5525.   | 5.2  | 11        |
| 16 | Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 117-121.   | 0.4  | 9         |
| 17 | Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 3186-3186.   | 1.4  | 9         |
| 18 | Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. <i>Blood</i> , 2017, 130, 900-900.  | 1.4  | 9         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. <i>Molecular Cancer</i> , 2021, 20, 134.  | 19.2 | 9         |
| 20 | Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study. <i>Blood</i> , 2021, 138, 606-606.   | 1.4  | 9         |
| 21 | Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia. <i>Leukemia and Lymphoma</i> , 2020, 61, 225-227. | 1.3  | 8         |
| 22 | Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. <i>Blood</i> , 2018, 132, 792-792.   | 1.4  | 8         |
| 23 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castlemans Disease. <i>Blood</i> , 2013, 122, 505-505.                             | 1.4  | 7         |
| 24 | Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2019, 110, 709-722.   | 1.6  | 6         |
| 25 | Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. <i>Transfusion</i> , 2019, 59, 335-339.   | 1.6  | 6         |
| 26 | The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. <i>Singapore Medical Journal</i> , 2017, 58, 55-71.  | 0.6  | 6         |
| 27 | Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia. <i>Blood</i> , 2020, 136, 43-44.  | 1.4  | 6         |
| 28 | Newly diagnosed and previously treated multicentric Castlemans disease respond equally to siltuximab. <i>British Journal of Haematology</i> , 2021, 192, e28-e31.   | 2.5  | 4         |
| 29 | Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7009-7009.  | 1.6  | 4         |
| 30 | Tumor infiltrating lymphocytes from acute myeloid leukemia marrow can be reverted to CD45RA+ central memory state by reactivation in SIP (Simulated Infective Protocol). <i>Immunobiology</i> , 2019, 224, 526-531.   | 1.9  | 3         |
| 31 | The M351T BCR-ABL Kinase Mutation Is Uncommon in Asian Patients with Imatinib-Resistant Chronic Myeloid Leukemia: Possible Relationship with Imatinib Plasma Levels.. <i>Blood</i> , 2008, 112, 2122-2122.  | 1.4  | 3         |
| 32 | Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].. <i>Journal of Clinical Oncology</i> , 2022, 40, 7061-7061.                                    | 1.6  | 3         |
| 33 | A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). <i>Blood Cancer Journal</i> , 2021, 11, 150.  | 6.2  | 2         |
| 34 | Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy. <i>Blood</i> , 2010, 116, 2883-2883.   | 1.4  | 2         |
| 35 | Cytokine Induced Killer Cells Are Feasible and Safe for Both Autologous and Allogeneic Applications in Patients with Haematological Malignancies. <i>Blood</i> , 2008, 112, 2917-2917.  | 1.4  | 2         |
| 36 | Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: 8-y update of a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7549-7549.   | 1.6  | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Treatment outcomes of T and natural killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. Cancer Reports, 2022, , e1552.   | 1.4 | 2         |
| 38 | Studies of Wilms Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore. Biomarker Insights, 2007, 2, 117727190700200.  | 2.5 | 1         |
| 39 | Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status.. Journal of Clinical Oncology, 2021, 39, e19039-e19039.   | 1.6 | 1         |
| 40 | Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas. Blood, 2018, 132, 4165-4165.   | 1.4 | 1         |
| 41 | Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells. Blood, 2020, 136, 35-36.  | 1.4 | 1         |
| 42 | The Leukemias. , 2004, , 581-600.  |     | 0         |
| 43 | Risk of Hepatitis B Virus (HBV) Reactivation and the Role of Anti-Viral Prophylaxis in Multiple Myeloma Patients with HBV Infection in the Era of Novel Therapies.. Blood, 2009, 114, 3882-3882.   | 1.4 | 0         |
| 44 | Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response. Blood, 2010, 116, 3056-3056.  | 1.4 | 0         |
| 45 | Essential Thrombocythaemia in Young Adults: Clinical Characteristics and Outcomes – a Single Center Experience. Blood, 2012, 120, 5060-5060.   | 1.4 | 0         |
| 46 | Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response. Blood, 2012, 120, 3669-3669.  | 1.4 | 0         |
| 47 | A Case of Two Young Brothers with Natural-Killer/T-Cell Lymphoma. Blood, 2016, 128, 5293-5293.   | 1.4 | 0         |
| 48 | Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort. Blood, 2016, 128, 1871-1871.  | 1.4 | 0         |
| 49 | Predictors of Delayed Clearance and Toxicities from High Dose Methotrexate in Patients Receiving Hypercvad Regimen for Treatment of Lymphoid Malignancies. Blood, 2016, 128, 1630-1630.  | 1.4 | 0         |
| 50 | In Vitro Expanded $\gamma\delta$ T Cells Derived from Cord Blood Induce Potent and Specific Cytotoxicity Against Human Acute Myeloid Leukemia Cells. Blood, 2016, 128, 2168-2168.  | 1.4 | 0         |
| 51 | Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases. Blood, 2018, 132, 2885-2885.   | 1.4 | 0         |
| 52 | Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies. Blood, 2018, 132, 5637-5637. | 1.4 | 0         |
| 53 | No association between <i>ECSIT</i> germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma. Haematologica, 2021, 106, 1737-1739.  | 3.5 | 0         |
| 54 | Differential Activation of $V\gamma 4V\delta 1$ and $V\gamma 9V\delta 2$ Cord Blood Derived Gamma Delta T Cells upon Exposure to EBV-Lcl and K562 Cells. Blood, 2021, 138, 2790-2790.  | 1.4 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. <i>Blood</i> , 2020, 136, 30-31.   | 1.4 | 0         |
| 56 | Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies - 15-Year Follow-up of Multicenter Study in Singapore. <i>Blood</i> , 2020, 136, 22-23. | 1.4 | 0         |
| 57 | Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide. <i>Blood</i> , 2020, 136, 25-26.                                     | 1.4 | 0         |